Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. 1996

H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
Department of Angiology and Geriatrics, Medical University Lübeck, Germany.

The potential influence of pantoprazole (BY1023/SK&F96022), a newly developed selective inhibitor of the gastric H+,K(+)-ATPase, on therapeutic serum theophylline concentrations was investigated in a crossover study in 8 healthy male volunteers (age 25-30 [median 27] years, body weight 63-80 [median 68] kg). Steady-state serum theophylline concentrations were obtained by a two-step intravenous infusion scheme of approximately 350 mg theophylline each over 0.5 h and subsequently over approximately 10 h, respectively. In the test period, 30 mg pantoprazole were injected over 2 min on 5 consecutive days and theophylline was infused on day 4. In the reference period, placebo was administered i.v. on 2 consecutive days and theophylline on day 1. Serum pantoprazole concentrations were measured up to 12 h, serum theophylline concentrations up to 36 h. Pantoprazole was well tolerated with and without theophylline. There were no clinically relevant changes in blood pressure, heart rate, ECG and routine clinical laboratory parameters. Primary characteristic for confirmative assessment of no interaction was the area under the concentration/time curve (AUC). Lack of interaction in the sense of equivalence was concluded both for theophylline (with and without pantoprazole) and pantoprazole (with and without theophylline), as the 90%-confidence intervals of the AUC-ratio test/reference were within the equivalence range of 0.8 to 1.25. Further explorative analysis of theophylline disposition kinetics revealed this inclusion also for clearance and volume of distribution, but not for the half-life. In the case of pantoprazole, the corresponding 90%-confidence intervals for any of the secondary characteristics clearance, volume of distribution and half-life were within the above mentioned range. In conclusion, repeated once-daily i.v. injections of 30 mg pantoprazole have no clinically relevant influence on steady-state theophylline serum concentrations, nor does theophylline at therapeutic serum concentrations influence the pantoprazole disposition kinetics. Hence, in clinical practice theophylline and pantoprazole can be administered concomitantly without dose adjustment.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077402 Pantoprazole 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER. BY 1023,BY-1023,Pantoprazole Sodium,Protonix,SK&F 96022,SK&F-96022,SKF-96022,BY1023,SK&F96022,SKF 96022,SKF96022
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
June 1987, Southern medical journal,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
July 1983, Journal of clinical pharmacology,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
August 1994, International journal of clinical pharmacology and therapeutics,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
February 1980, Clinical pharmacology and therapeutics,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
September 1999, British journal of clinical pharmacology,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
March 2000, Alimentary pharmacology & therapeutics,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
July 1987, British journal of clinical pharmacology,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
August 1980, Journal of pharmacokinetics and biopharmaceutics,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
February 1970, Chemical & pharmaceutical bulletin,
H U Schulz, and M Hartmann, and V W Steinijans, and R Huber, and B Lührmann, and H Bliesath, and W Wurst
July 1977, The American review of respiratory disease,
Copied contents to your clipboard!